FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:220-222 July 18, 2002 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kaplan, A. P. PubMed Citation

To the Editor: In his review of chronic urticaria and angioedema (Jan. 17 issue),¹ Kaplan recommends doses of fexofenadine, cetirizine, and loratadine as high as twice the doses recommended on the package labels for the control of pruritus and hives. The results of clinical trials that were submitted to the Food and Drug Administration (FDA) and that formed the basis of approval and dose recommendations for the use of these drugs in patients with chronic urticaria do not support the author's recommendation, nor do data in the published literature.

For drugs proposed for the treatment of chronic urticaria, the FDA . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.